New statin guidelines are an improvement, study shows

August 26, 2014 by Jim Shelton
New statin guidelines are an improvement, Yale study shows

(Medical Xpress)—New national guidelines can improve the way statin drugs are prescribed to patients at risk for cardiovascular disease, a Yale University study has found.

The research, published Aug. 25 in the Journal of the American College of Cardiology, also showed the new produce only a modest increase in the number of patients being given the drugs.

Statins are a class of drugs that help lower cholesterol by blocking the enzyme HMG-CoA reductase, which the body needs in order to produce cholesterol. Common statin medications include Lipitor, Levacor, Zocor, Pravachol, and Crestor.

In 2013, the American Heart Association and the American College of Cardiology jointly published a new set of standards for the assessment of . The standards replaced the 2001 National Cholesterol Education Program Adult Treatment Panel III recommendations.

"There has been a great deal of discussion about the new guidelines. People worry whether the new risk equation is accurate," said Dr. Kevin M. Johnson, lead author of the study and associate professor of diagnostic radiology at the Yale School of Medicine. "They are concerned that too many people will be put on statins."

Johnson and co-author Dr. David A. Dowe of Atlantic Medical Imaging, in Galloway, N.J., studied 3,076 subjects. They applied both sets of guidelines to determine whether patients would start .

They found that the new guidelines did a better job of discriminating between patients with little or no plaque and those with more plaque. Of patients with heavy plaque, 92% would be assigned to statin therapy under the new method, but only 53% under the old standards.

The biggest difference between the two results, researchers said, was the use of low-density lipoprotein (LDL) cholesterol targets under the old guidelines. The targets "seriously degraded the accuracy of the NCEP guideline for statin assignment," according to the study.

"The old guidelines emphasized lowering LDL cholesterol to certain target values, but the new guidelines have done away with that approach," Johnson said. "Many doctors are reluctant to give up targets."

Overall, 15% more patients would be put on statins under the new guidelines—considerably fewer than some observers had predicted, he added.

The researchers noted that they used coronary atherosclerotic plaque burden as the determining factor in the study, rather than cardiac events. Further study will be necessary to evaluate the guidelines with outcome data.

Explore further: ACC/AHA publish new guideline for management of blood cholesterol

Related Stories

ACC/AHA publish new guideline for management of blood cholesterol

November 12, 2013

The American College of Cardiology and the American Heart Association today released a new clinical practice guideline for the treatment of blood cholesterol in people at high risk for cardiovascular diseases caused by atherosclerosis, ...

Large variation in lipid reduction with high-dose statin tx

July 31, 2014

(HealthDay)—There is considerable interindividual variation in the magnitude of low-density lipoprotein cholesterol (LDL-C), non-high-density lipoprotein cholesterol (non-HDL-C), and apolipoprotein B (apoB) reductions achieved ...

Recommended for you

Heart attack treatment hypothesis 'busted'

July 6, 2015

Researchers have long had reason to hope that blocking the flow of calcium into the mitochondria of heart and brain cells could be one way to prevent damage caused by heart attacks and strokes. But in a study of mice engineered ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.